代谢组学与心力衰竭相关研究及进展
|
摘要
代谢组学作为继基因组学、转录组学和蛋白质组学等之后兴起的另一个系统生物学分支,能够揭示疾病发生发展的机制,发现和筛选体液标志物并且为探索诊断及治疗靶点提供有用信息,目前已广泛应用于心力衰竭病理生理机制的解释及诊疗之中,将成为心力衰竭诊疗全新出路。
Metabolomics as a branch of biology after genomics,transcriptomics,and proteomics,can reveal the mechanisms by which discover and explore diagnostic and therapeutic targets of heart failure,and provides useful information.It will become a new way out for diagnosis and treatment in heart failure.
Metabolomics as a branch of biology after genomics,transcriptomics,and proteomics,can reveal the mechanisms by which discover and explore diagnostic and therapeutic targets of heart failure,and provides useful information.It will become a new way out for diagnosis and treatment in heart failure.
引文
[1]Qaddoura A,Yazdanashoori P,Kabali C,et al.Efficacy of Hospital at Home in Patients with Heart Failure:ASystematic Review and Meta-Analysis[J].Plos One,2015,10(6):e0129282.
[2]庞博,王斌,舒振波,等.慢性心功能衰竭患者尿液的代谢组学研究[J].分析化学,2017,45(8):1165-1171.
[3]Marcinkiewicz-Siemion M,Ciborowski M,Kretowski A,et al.Metabolomics-A wide-open door to personalized treatment in chronic heart failure?[J].Int J Cardiol,2016,219:156-163.
[4]刘洋,赵冬梅,尹兴忠,等.心衰发病机制的研究进展[J].医学信息,2017,30(18):23-24.
[5]Doenst T,Nguyen TD,Abel ED.Cardiac metabolism in heart failure implications beyond ATP production[J].Circ Res,2013,113(6):709-724.
[6]Newgard C.Metabolomics and metabolic diseases:where do we stand?[J].Cell Metabol,2016,25(1):43-56.
[7]Cheng S,Shah SH,Corwin EJ,et al.Potential impact and study considerations of metabolomics in cardiovascular health and disease:a scientific statement from the American Heart Association[J].Circ Cardiovasc Genet,2017,10(2):e000032.
[8]Hirayama A,Kami K,Sugimoto M,et al.Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-offlight mass spectrometry[J].Cancer Res,2009,69(11):4918-4925.
[9]Zamboni N,Saghatelian A,Patti GJ.Defining the metabolome:size,flux,and regulation[J].Molecular Cell,2015,58(4):699-706.
[10]Yasushi M,Otoni CC,Steelman SM,et al.Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease[J].Gut Microbes,2015,6(1):33-47.
[11]Nam M,Jung Y,Ryu DH,et al.A metabolomics-driven approach reveals metabolic responses and mechanisms in the rat heart following myocardial infarction[J].Int J Cardiol,2016,227:111-112.
[12]田晓芳,王晓雪,李朋梅,等.基于代谢组学的心肌缺血药理学研究进展[J].中国药学杂志,2016,51(20):1726-1729.
[13]Wang Z,Elizabeth K,Bennett BJ,et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J].Nature,2011,472(7341):57-63.
[14]Suthahar N,Meijers WC,Brouwers FP,et al.Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population[J].Int J Cardiol,2018,250:188-189.
[15]Alonso A,Yu B,Qureshi W T,et al.Metabolomics and incidence of atrial fibrillation in African Americans:The Atherosclerosis Risk in Communities(ARIC)Study[J].Plos One,2015,10(11):e0142610.
[16]Andreadou I,Papaefthimiou M,Zira A,et al.Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein[J].Nmr in Biomed,2010,22(6):585-592.
[17]Ussher JR,Elmariah S,Gerszten RE,et al.The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease[J].JACC,2016,68(25):2850-2870.
[18]郑海生,蒋健.基于代谢组学慢性心力衰竭肾阳虚证代谢模式的研究[J].中国中医基础医学杂志,2017(5):645-647.
[19]陈静.基于证候要素辨证治疗慢性心衰的临床疗效评价及代谢组学研究[D].北京中医药大学,2016.
[20]Berezin AE.Biomarker-Guided Therapy for Chronic Heart Failure.Biomarkers in Disease:Methods,Discoveries and Applications,edited by Victor R.Preedy and Vinood B.Patel.Springer,Switzerland,2016.IS-BN 978-94-007-7677-7[M]//Biomarkers in Disease:Methods,Discoveries and Applications.2016.
[21]李新立,郑旭辉.心力衰竭生物标志物在我国的临床应用现况[J].临床心血管病杂志,2017,33(9):819-820.
[22]Bozkurt B,Mann DL,Deswal A.Biomarkers of inflammation in heart failure[J].Heart Fail Rev,2010,15(4):331-341.
[23]马丽娟,石亚男,刘巍.心房超声心动图对心力衰竭患者的应用价值[J].临床心血管病杂志,2017,33(6):10-13.
[24]贾晨平.心力衰竭药物治疗新进展[J].临床心血管病杂志,2017,33(6):601-604.
[25]Lewis GD,Farrell L,Wood MJ,et al.Metabolic signatures of exercise in Human plasma[J].Sci Translat Med,2010,2(33):33ra37.
[26]Ikegami R,Shimizu I,Yoshida Y,et al.Metabolomic analysis in heart failure[J].Circ J,2017,82(1):111-112.
[27]刘蓓蕾,吴钢.心脏疾病与能量代谢关系研究进展[J].疑难病杂志,2018,32(2):199-202.
[28]De Jong KA,Lopaschuk GD.Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction[J].Can J Cardiol,2017,33(7):860-861.
[29]Jr BK,Snyder NW,Brandimarto J,et al.Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure[J].Circulation,2016,133(8):706-706.
[30]Tuunanen H,Engblom E,Naum A,et al.Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy:evidence of relationship with insulin resistance and left ventricular dysfunction[J].J Card Fail,2006,12(8):644-652.
[31]Ahmad T,Kelly J P,Mcgarrah R W,et al.Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support[J].JACC,2016,67(3):291-291.
[32]Rennison JH,Mcelfresh TA,Okere IC,et al.Enhanced acyl-CoA dehydrogenase activity is associated with improved mitochondrial and contractile function in heart failure[J].Cardiovasc Res,2008,79(2):331-340.
[33]Sansbury BE,Demartino AM,Xie Z,et al.Metabolomic analysis of pressure-overloaded and infarcted mouse hearts[J].Circ Heart Fail,2014,7(4):634-642.
[34]Iqbal J,Walsh MT,Hammad SM,et al.Sphingolipids and lipoproteins in health and metabolic disorders[J].Trends Endocrinol Metab Tem,2017,28(7):506-506.
[35]Keul P,Borren MM,Ghanem A,et al.Sphingosine‐1‐phosphate receptor 1regulates cardiac function by modulating Ca2+sensitivity and Na+/H+exchange and mediates protection by ischemic preconditioning[J].J Am Heart Assoc,2016,5(5):e003393.
[36]Polzin A,Piayda K,Keul P,et al.Plasma sphingosine-1-phosphate concentrations are associated with systolic heart failure in patients with ischemic heart disease[J].J Mol Cell Cardiol,2017,110.
[37]Cannavo A,Rengo G,Liccardo D,et al.β1-blockade prevents post-ischemic myocardial decompensation viaβ3AR-dependent protective sphingosine-1 pignaling[J].JACC,2017,70(2):182-182.
[38]Pan W,Yu J,Shi R,et al.Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes[J].Coron Artery Dis,2014,25(3):230-235.
[39]Yu J,Pan W,Shi R,et al.Ceramide is upregulated and associated with mortality in patients with chronic heart failure[J].Can J Cardiol,2015,31(3):357-63.
[40]Holland WL,Miller RA,Wang ZV,et al.Receptormediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin[J].Nat Med,2011,17(1):55-63.
[41]Parra V,Moraga F,Kuzmicic J,et al.Calcium and mitochondrial metabolism in ceramide-induced cardiomyocyte death[J].Biochim Biophys Acta,2013,1832(8):1334-1344.
[42]Desmoulin F,Galinier M,Trouillet C,et al.Metabonomics analysis of plasma reveals the lactate to cholesterol ratio as an independent prognostic factor of short-term mortality in acute heart failure[J].PLoSOne,2013,8(4):e60737.
[43]Mirtschink P,Krishnan J,Grimm F,et al.HIF-driven SF3B1induces KHK-C to enforce fructolysis and heart disease[J].Nature,2015,522(7557):444-449.
[44]Aquilani R,Rovere MTL,Corbellini D,et al.Plasma amino acid abnormalities in chronic heart failure.mechanisms,potential risks and targets in human myocardium metabolism[J].Nutrients,2017,9(11):1251-1252.
[45]王娟,赵慧辉,陈建新,等.慢性心力衰竭血瘀证患者血浆代谢物研究[J].北京中医药大学学报,2016,39(2):101-105.
[46]Deidda M,Piras C,Dessalvi CC,et al.Metabolomic approach to profile functional and metabolic changes in heart failure[J].J Transl Med,2015,13(1):297-300.
[47]Cheng ML,Wang CH,Shiao MS,et al.Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure:diagnostic and prognostic value of metabolomics[J].JACC,2015,65(15):1509-1520.
[48]Ferrannini E,Baldi S,Frascerra S,et al.Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2inhibition in subjects without diabetes and patients with type 2diabetes[J].J Food Sc Technol,2016,52(6):3158-3168.
[49]Zinman B,Wanner C,Lachin JM,et al.Cardiovascular outcomes,and mortality in type 2diabetes[J].N Engl J Med,2015,373(22):2117-2128.
[50]Mudaliar S,Alloju S,Henry R R.Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study?A Unifying Hypothesis[J].Diabetes Care,2016,39(7):1115-1122.
[51]Tang WHW,Wang Z,Fan Y,et al.Prognostic value of elevated levels of intestinal microbe-generated metabolite Trimethylamine-N-oxide in patients with heart failure[J].JACC,2013,61(10):1908-1914.
[52]Lever M,George PM,Slow S,et al.Betaine and Trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus:an observational study[J].PLoS One,2014,9(12):e114969.
[2]庞博,王斌,舒振波,等.慢性心功能衰竭患者尿液的代谢组学研究[J].分析化学,2017,45(8):1165-1171.
[3]Marcinkiewicz-Siemion M,Ciborowski M,Kretowski A,et al.Metabolomics-A wide-open door to personalized treatment in chronic heart failure?[J].Int J Cardiol,2016,219:156-163.
[4]刘洋,赵冬梅,尹兴忠,等.心衰发病机制的研究进展[J].医学信息,2017,30(18):23-24.
[5]Doenst T,Nguyen TD,Abel ED.Cardiac metabolism in heart failure implications beyond ATP production[J].Circ Res,2013,113(6):709-724.
[6]Newgard C.Metabolomics and metabolic diseases:where do we stand?[J].Cell Metabol,2016,25(1):43-56.
[7]Cheng S,Shah SH,Corwin EJ,et al.Potential impact and study considerations of metabolomics in cardiovascular health and disease:a scientific statement from the American Heart Association[J].Circ Cardiovasc Genet,2017,10(2):e000032.
[8]Hirayama A,Kami K,Sugimoto M,et al.Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-offlight mass spectrometry[J].Cancer Res,2009,69(11):4918-4925.
[9]Zamboni N,Saghatelian A,Patti GJ.Defining the metabolome:size,flux,and regulation[J].Molecular Cell,2015,58(4):699-706.
[10]Yasushi M,Otoni CC,Steelman SM,et al.Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease[J].Gut Microbes,2015,6(1):33-47.
[11]Nam M,Jung Y,Ryu DH,et al.A metabolomics-driven approach reveals metabolic responses and mechanisms in the rat heart following myocardial infarction[J].Int J Cardiol,2016,227:111-112.
[12]田晓芳,王晓雪,李朋梅,等.基于代谢组学的心肌缺血药理学研究进展[J].中国药学杂志,2016,51(20):1726-1729.
[13]Wang Z,Elizabeth K,Bennett BJ,et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J].Nature,2011,472(7341):57-63.
[14]Suthahar N,Meijers WC,Brouwers FP,et al.Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population[J].Int J Cardiol,2018,250:188-189.
[15]Alonso A,Yu B,Qureshi W T,et al.Metabolomics and incidence of atrial fibrillation in African Americans:The Atherosclerosis Risk in Communities(ARIC)Study[J].Plos One,2015,10(11):e0142610.
[16]Andreadou I,Papaefthimiou M,Zira A,et al.Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein[J].Nmr in Biomed,2010,22(6):585-592.
[17]Ussher JR,Elmariah S,Gerszten RE,et al.The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease[J].JACC,2016,68(25):2850-2870.
[18]郑海生,蒋健.基于代谢组学慢性心力衰竭肾阳虚证代谢模式的研究[J].中国中医基础医学杂志,2017(5):645-647.
[19]陈静.基于证候要素辨证治疗慢性心衰的临床疗效评价及代谢组学研究[D].北京中医药大学,2016.
[20]Berezin AE.Biomarker-Guided Therapy for Chronic Heart Failure.Biomarkers in Disease:Methods,Discoveries and Applications,edited by Victor R.Preedy and Vinood B.Patel.Springer,Switzerland,2016.IS-BN 978-94-007-7677-7[M]//Biomarkers in Disease:Methods,Discoveries and Applications.2016.
[21]李新立,郑旭辉.心力衰竭生物标志物在我国的临床应用现况[J].临床心血管病杂志,2017,33(9):819-820.
[22]Bozkurt B,Mann DL,Deswal A.Biomarkers of inflammation in heart failure[J].Heart Fail Rev,2010,15(4):331-341.
[23]马丽娟,石亚男,刘巍.心房超声心动图对心力衰竭患者的应用价值[J].临床心血管病杂志,2017,33(6):10-13.
[24]贾晨平.心力衰竭药物治疗新进展[J].临床心血管病杂志,2017,33(6):601-604.
[25]Lewis GD,Farrell L,Wood MJ,et al.Metabolic signatures of exercise in Human plasma[J].Sci Translat Med,2010,2(33):33ra37.
[26]Ikegami R,Shimizu I,Yoshida Y,et al.Metabolomic analysis in heart failure[J].Circ J,2017,82(1):111-112.
[27]刘蓓蕾,吴钢.心脏疾病与能量代谢关系研究进展[J].疑难病杂志,2018,32(2):199-202.
[28]De Jong KA,Lopaschuk GD.Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction[J].Can J Cardiol,2017,33(7):860-861.
[29]Jr BK,Snyder NW,Brandimarto J,et al.Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure[J].Circulation,2016,133(8):706-706.
[30]Tuunanen H,Engblom E,Naum A,et al.Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy:evidence of relationship with insulin resistance and left ventricular dysfunction[J].J Card Fail,2006,12(8):644-652.
[31]Ahmad T,Kelly J P,Mcgarrah R W,et al.Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support[J].JACC,2016,67(3):291-291.
[32]Rennison JH,Mcelfresh TA,Okere IC,et al.Enhanced acyl-CoA dehydrogenase activity is associated with improved mitochondrial and contractile function in heart failure[J].Cardiovasc Res,2008,79(2):331-340.
[33]Sansbury BE,Demartino AM,Xie Z,et al.Metabolomic analysis of pressure-overloaded and infarcted mouse hearts[J].Circ Heart Fail,2014,7(4):634-642.
[34]Iqbal J,Walsh MT,Hammad SM,et al.Sphingolipids and lipoproteins in health and metabolic disorders[J].Trends Endocrinol Metab Tem,2017,28(7):506-506.
[35]Keul P,Borren MM,Ghanem A,et al.Sphingosine‐1‐phosphate receptor 1regulates cardiac function by modulating Ca2+sensitivity and Na+/H+exchange and mediates protection by ischemic preconditioning[J].J Am Heart Assoc,2016,5(5):e003393.
[36]Polzin A,Piayda K,Keul P,et al.Plasma sphingosine-1-phosphate concentrations are associated with systolic heart failure in patients with ischemic heart disease[J].J Mol Cell Cardiol,2017,110.
[37]Cannavo A,Rengo G,Liccardo D,et al.β1-blockade prevents post-ischemic myocardial decompensation viaβ3AR-dependent protective sphingosine-1 pignaling[J].JACC,2017,70(2):182-182.
[38]Pan W,Yu J,Shi R,et al.Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes[J].Coron Artery Dis,2014,25(3):230-235.
[39]Yu J,Pan W,Shi R,et al.Ceramide is upregulated and associated with mortality in patients with chronic heart failure[J].Can J Cardiol,2015,31(3):357-63.
[40]Holland WL,Miller RA,Wang ZV,et al.Receptormediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin[J].Nat Med,2011,17(1):55-63.
[41]Parra V,Moraga F,Kuzmicic J,et al.Calcium and mitochondrial metabolism in ceramide-induced cardiomyocyte death[J].Biochim Biophys Acta,2013,1832(8):1334-1344.
[42]Desmoulin F,Galinier M,Trouillet C,et al.Metabonomics analysis of plasma reveals the lactate to cholesterol ratio as an independent prognostic factor of short-term mortality in acute heart failure[J].PLoSOne,2013,8(4):e60737.
[43]Mirtschink P,Krishnan J,Grimm F,et al.HIF-driven SF3B1induces KHK-C to enforce fructolysis and heart disease[J].Nature,2015,522(7557):444-449.
[44]Aquilani R,Rovere MTL,Corbellini D,et al.Plasma amino acid abnormalities in chronic heart failure.mechanisms,potential risks and targets in human myocardium metabolism[J].Nutrients,2017,9(11):1251-1252.
[45]王娟,赵慧辉,陈建新,等.慢性心力衰竭血瘀证患者血浆代谢物研究[J].北京中医药大学学报,2016,39(2):101-105.
[46]Deidda M,Piras C,Dessalvi CC,et al.Metabolomic approach to profile functional and metabolic changes in heart failure[J].J Transl Med,2015,13(1):297-300.
[47]Cheng ML,Wang CH,Shiao MS,et al.Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure:diagnostic and prognostic value of metabolomics[J].JACC,2015,65(15):1509-1520.
[48]Ferrannini E,Baldi S,Frascerra S,et al.Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2inhibition in subjects without diabetes and patients with type 2diabetes[J].J Food Sc Technol,2016,52(6):3158-3168.
[49]Zinman B,Wanner C,Lachin JM,et al.Cardiovascular outcomes,and mortality in type 2diabetes[J].N Engl J Med,2015,373(22):2117-2128.
[50]Mudaliar S,Alloju S,Henry R R.Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study?A Unifying Hypothesis[J].Diabetes Care,2016,39(7):1115-1122.
[51]Tang WHW,Wang Z,Fan Y,et al.Prognostic value of elevated levels of intestinal microbe-generated metabolite Trimethylamine-N-oxide in patients with heart failure[J].JACC,2013,61(10):1908-1914.
[52]Lever M,George PM,Slow S,et al.Betaine and Trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus:an observational study[J].PLoS One,2014,9(12):e114969.